key: cord-0329282-bncexgr3
authors: Wagner, Teresa R.; Schnepf, Daniel; Beer, Julius; Klingel, Karin; Ruetalo, Natalia; Kaiser, Philipp D.; Junker, Daniel; Sauter, Martina; Traenkle, Bjoern; Frecot, Desiree I.; Becker, Matthias; Schneiderhan-Marra, Nicole; Ohnemus, Annette; Schwemmle, Martin; Schindler, Michael; Rothbauer, Ulrich
title: A broadly neutralizing biparatopic Nanobody protects mice from lethal challenge with SARS-CoV-2 variants of concern
date: 2021-08-09
journal: bioRxiv
DOI: 10.1101/2021.08.08.455562
sha: 71ede72501d948e627e53ddf5e12306dabb28dd7
doc_id: 329282
cord_uid: bncexgr3

The ongoing COVID-19 pandemic and the frequent emergence of new SARS-CoV-2 variants of concern (VOCs), requires continued development of fast and effective therapeutics. Recently, we identified high-affinity neutralizing nanobodies (Nb) specific for the receptor-binding domain (RBD) of SARS-CoV-2, which are now being used as biparatopic Nbs (bipNbs) to investigate their potential as future drug candidates. Following detailed in vitro characterization, we chose NM1267 as the most promising candidate showing high affinity binding to several recently described SARS-CoV-2 VOCs and strong neutralizing capacity against a patient isolate of B.1.351 (Beta). To assess if bipNb NM1267 confers protection against SARS-CoV-2 infection in vivo, human ACE2 transgenic mice were treated by intranasal route before infection with a lethal dose of SARS-CoV-2. NM1267-treated mice showed significantly reduced disease progression, increased survival rates and secreted less infectious virus via their nostrils. Histopathological analyses and in situ hybridization further revealed a drastically reduced viral load and inflammatory response in lungs of NM1267-treated mice. These data suggest, that bipNb NM1267 is a broadly active and easily applicable drug candidate against a variety of emerging SARS-CoV-2 VOCs.

The ongoing SARS-CoV-2 pandemic continues to be challenging due to limited access to 55 vaccines in certain countries or vaccine fatigue in others, the lack of effective and easy-to-56 administer antivirals, and the emergence of variants of concern (VOCs) (Scudellari, 2020) . 57

Despite the rapid development of effective vaccines, global immunity or alternatively 58 eradication of SARS-CoV-2 is currently out of reach (Dagan et al, 2021; Kwok et al, 2020) . In Recently, we reported the identification of several Nbs demonstrating a high neutralizing 87 capacity against SARS-CoV-2 and generated a biparatopic (bip) Nb (NM1267) that binds two 88 distinct sites, one epitope inside and one outside of the RBD:ACE2 interface (Wagner et al., 89 2021 Following our recently reported approach in which we combined two Nbs targeting different 104 epitopes within the RBD of SARS-CoV-2 to generate the strongly neutralizing biparatopic Nb 105 (bipNb) NM1267 (Wagner et al., 2021) , we designed two additional bipNbs. We genetically 106 coupled Nbs NM1230 and NM1228, which both bind within the RBD:ACE2 interface, and 107 NM1228 and NM1226, of which the latter targets an epitope outside the RBD:ACE2 interface, 108 via a flexible Gly-Ser ((G4S)4) linker, resulting in the bipNbs NM1266 and NM1268, respectively 109 Table 1 ). Similar to NM1267 (Wagner et al., 2021) , both novel bipNbs were 110 produced with a high yield and good purity in mammalian cells and showed picomolar affinities 111 to wild-type (WT) RBD as measured by biolayer interferometry (BLI) ( Figure 1A ). To test their 112 potency to block the interaction between RBD, S1, or spike of SARS-CoV-2 to human ACE2, 113

we performed a recently established multiplex ACE2 competition assay (Wagner et al., 2021) . 114

The results showed that both bipNbs inhibited binding of ACE2 to all tested antigens in the low 115 picomolar range (Supplementary Figure 1A, C) . Additionally, we confirmed their neutralizing 116 effect in a VNT using SARS-CoV-2 WT which revealed half maximal inhibitory concentrations 117 (IC50s) in the nano-or picomolar range (Supplementary Figure 1B) . Notably, NM1267 proved 118 to be the most potent bipNb in this assay with an IC50 of 380 pM (Supplementary Figure 1C) . 119

For further selection, we next assessed the biophysical properties of all three bipNbs by 120 measuring thermal unfolding and aggregation with nano differential scanning fluorimetry 121 (nanoDSF) (Figure 1B) . While the bipNbs NM1267 and NM1268, both containing the Nb 122 NM1226, showed a slight increase in light scattering, indicating a higher aggregation tendency 123 at higher, non-physiological temperatures, NM1266 showed no onset of aggregation up to 124 90°C. Reanalysis after accelerated aging at 37°C for ten days revealed no considerable 125 differences compared to baseline ( Figure 1B) . From these data, we concluded that all three 126 bipNbs are highly stable. However, as NM1267 showed the highest melting temperature of 127 ~57°C (Figure 1B) , indicating improved thermal stability, we decided to proceed with the bipNb 128 NM1267 as our favorite candidate for the intended in vivo application. 129

Previously, we had shown that the individual Nbs linked to form NM1267 (NM1230 and 130 NM1226) both exhibit strong neutralization potency regardless of whether they bind within the 131 RBD:ACE2 interface, as shown for NM1230, or bind a more conserved region outside this 132 interaction site, as shown for NM1226 (Wagner et al., 2021) (Supplementary Figure 2) . With 133 the precise epitopes known, we considered that NM1267 could also be effective against lately 134 described VOCs, since only mild binding interference were expected due to the acquired 135 mutations (Supplementary Figure 2) . Therefore, we analyzed binding affinities of NM1267 136 towards RBDs of emerging SARS-CoV-2 variants using BLI (Figure 2A-I) . Compared to 137

RBDwt, NM1267 showed similar or even better binding to RBDs from B.1.1.7 (Alpha) ( Figure  138 The ongoing COVID-19 pandemic and the frequent emergence of new SARS-CoV-2 variants 197 of concern highlight the need of easily applicable therapeutic options. In addition to Nabs, Nbs 198 targeting the RBD of SARS-CoV-2 offer a promising alternative. Not only their stable folding, 199 robust biochemical properties, and ease of functionalization/ multimerization, but also the lack 200 of an Fc moiety that prevents severe adverse events such as ADE and their low 201 immunogenicity underlines the potential of Nbs as advanced therapeutic tools (Muyldermans, Recently, we identified neutralizing Nbs and showed their applicability to quantify neutralizing 208 antibodies in serum from convalescent and immunized individuals (Becker et al., 2021; 209 Wagner et al., 2021) . In this study, we investigated the therapeutic potential of multiple 210 biparatopic Nbs that jointly target different epitopes within the RBD. All bipNbs revealed 211 comparable picomolar affinities to RBDWT, strong ACE2 displacement and high neutralization 212 capacities. However, since NM1267 showed the highest thermal stability and detailed data on 213 the recognized epitopes were already available (Wagner et al., 2021) , we selected NM1267 214 as most promising drug candidate. Hypothesizing that combinatorial binding to epitopes within 215 the RBD:ACE2 interface and to conserved epitopes outside this interaction site might be 216 beneficial to also cover emerging VOCs, we were subsequently able to show strong binding of 217 NM1267 to all SARS-CoV-2 RBD variants tested. We further, demonstrated a high neutralizing 218 capacity of NM1267 for SARS-CoV-2 WT and the B. Given the poor access to vaccines in various countries, vaccination fatigue and the frequent 248 emergence of new variants of concern, we believe that the development of such easily 249 applicable therapeutic approaches to protect and treat predisposed individuals are highly 250 promising strategies and urgently warranted. 251

To generate described expression constructs all used primer sequences are listed in 254 

Binding affinity of bipNbs towards variants of RBD was determined via biolayer interferometry 304 (BLI) using the Octet RED96e system according to standard protocol. Therefore, RBD variants 305 were biotinylated and immobilized on streptavidin biosensors (SA, Sartorius). Dilution series 306 ranging from 5-0.625 nM of bipNbs were applied and one reference was included per run. For 307 affinity determination, the 1:1 global fit of the Data Analysis HT 12.0 software was used. 308 309

To analyze binding competition of human ACE2 versus generated bipNbs the bead-based 311 multiplex ACE2 competition assay was performed as previously described (Wagner et al., 312 2021) . 

Caco-2 (Human Colorectal adenocarcinoma, ATCC HTB-37) cells were cultured at 37°C with 336 5% CO2 in DMEM containing 10% FCS, 2 mM l-glutamine, 100 μg/ ml penicillin-streptomycin 337 and 1% NEAA. 338

Neutralization assays using clinical isolates (Figure 3A-C 

The data that support the findings of this study are available from the corresponding authors 390 upon reasonable request. 

Decline of humoral responses against SARS-CoV-2 521 spike in convalescent individuals

Immune response to SARS-CoV-2 variants of concern in 524 vaccinated individuals

Potent neutralizing antibodies from COVID-19 527 patients define multiple targets of vulnerability

Potent 529 neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell 530 sequencing of convalescent patients' B cells

Risk 532 of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort 533 study

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with 536 Covid-19

Humanized 538 single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding 539 domain

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination 542 setting

Washburne AD et al (2021a) Estimated transmissibility and impact of SARS-545

CoV-2 lineage B.1.1.7 in England

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and 551 serum-derived polyclonal antibodies

Nasal delivery of single-domain antibodies improves 554 symptoms of SARS-CoV-2 infection in an animal model

Six-month 556 follow-up chest CT findings after severe COVID-19 pneumonia

A bispecific monomeric nanobody induces SARS-COV-2 spike 559 trimer dimers

An alpaca nanobody neutralizes SARS-CoV-2 by 562 blocking receptor interaction

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block 565 interaction with ACE2

Monitoring differences between the SARS-CoV-2 B. 1.1. 7 variant and other 567 lineages. The Lancet Public Health

Neutralizing antibodies against SARS-CoV-2 and other human 569 coronaviruses

Human 571 neutralizing antibodies elicited by SARS-CoV-2 infection

Structure-guided multivalent nanobodies block SARS-CoV-574 2 infection and suppress mutational escape

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern 577 in BNT162b2-mRNA-vaccinated individuals

Herd immunity-estimating the level 579 required to halt the COVID-19 epidemics in affected countries

CoV-2 501Y. V2 variants lack higher infectivity but do have immune escape

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine 589 against the B.1.351 Variant

Lethal infection of K18-hACE2 mice infected with severe acute 592 respiratory syndrome coronavirus

Nanobodies: natural single-domain antibodies. Annual review of 594 biochemistry

Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 597 infections in Syrian hamsters at ultra-low doses

Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and 600 B. 1.351 variants to neutralizing antibodies

Antibody Response against SARS-CoV-2 and Seasonal 603 Coronaviruses in Nonhospitalized COVID-19 Patients

Drug development of an affinity enhanced, 606 broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents

How the pandemic might play out in 2021 and beyond

Fc receptors in 610 antibody-dependent enhancement of viral infections

Sixteen novel lineages of SARS-CoV-2 in South Africa

Antibody-dependent enhancement of virus infection and 615 disease

A novel epitope tagging 617 system to visualize and monitor antigens in live cells with chromobodies

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 621 in England

NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing 624 immune responses using nanobodies

Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7

Rofail 628 D, Im J et al (2020) REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-629 19

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe 632 lung inflammation and impaired function

Structural basis for potent neutralization of 635 betacoronaviruses by single-domain camelid antibodies

637 A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via 638 intranasal administration

Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2

An infectious cDNA clone of SARS-CoV-2

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk 646 factors, and treatments

Evidence of escape of SARS-CoV-2 variant B. 1.351 from 649 natural and vaccine-induced sera